Associates in Hematology-Oncology, PC

Chester, Pennsylvania 19130

0 studies enrolling now · 1 studies all time

What they study most

Low to Intermediate-1 MDS, MDS, Myelodysplastic Syndrome, Non-deletion 5q

Studies at this site

• A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients — Stopped early